{"id":71784,"date":"2026-08-06T00:37:34","date_gmt":"2026-08-05T16:37:34","guid":{"rendered":"https:\/\/flcube.com\/?p=71784"},"modified":"2026-08-06T00:37:35","modified_gmt":"2026-08-05T16:37:35","slug":"eli-lillys-kras-g12c-inhibitor-olomorasib-receives-second-fda-breakthrough-therapy-designation-for-advanced-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71784","title":{"rendered":"Eli Lilly&#8217;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy designation<\/strong> to <strong>olomorasib<\/strong> as a <strong>monotherapy<\/strong> for the treatment of <strong>adult patients with advanced pancreatic cancer<\/strong> who have received <strong>at least one prior systemic therapy<\/strong> and harbor a <strong>KRAS G12C mutation<\/strong>, as determined by an FDA-approved test.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Olomorasib (monotherapy)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced pancreatic cancer with KRAS G12C mutation<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>\u22651 prior systemic therapy<\/td><\/tr><tr><td><strong>Biomarker Requirement<\/strong><\/td><td>KRAS G12C mutation (FDA-approved test)<\/td><\/tr><tr><td><strong>Previous Designation<\/strong><\/td><td>NSCLC combination with KEYTRUDA\u00ae (first-line, PD-L1 \u226550%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-scientific-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Scientific Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type<\/strong>: Investigational, potent, and highly selective next-generation KRAS G12C inhibitor<\/li>\n\n\n\n<li><strong>Target Specificity<\/strong>: Specifically designed to target KRAS G12C mutation<\/li>\n\n\n\n<li><strong>Pharmacokinetic Advantages<\/strong>:<\/li>\n\n\n\n<li>High predicted target occupancy<\/li>\n\n\n\n<li>Potent inhibition in both monotherapy and combination regimens<\/li>\n\n\n\n<li><strong>Therapeutic Innovation<\/strong>: Addresses historically &#8220;undruggable&#8221; KRAS target with precision approach<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-regulatory-portfolio\" class=\"wp-block-heading\">Strategic Regulatory Portfolio<\/h2>\n\n\n\n<h3 id=\"h-dual-breakthrough-therapy-designations\" class=\"wp-block-heading\">Dual Breakthrough Therapy Designations<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer<\/strong> (New): Monotherapy for advanced disease post-first-line<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: Limited treatment options for KRAS G12C-mutated pancreatic cancer<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Heavily pre-treated with poor prognosis<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Non-Small Cell Lung Cancer<\/strong> (Previously Granted): Combination with KEYTRUDA\u00ae<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication<\/strong>: First-line locally advanced\/metastatic NSCLC<\/li>\n\n\n\n<li><strong>Biomarker Requirements<\/strong>: KRAS G12C mutation + PD-L1 expression \u226550%<\/li>\n\n\n\n<li><strong>Therapeutic Approach<\/strong>: Immunotherapy combination strategy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-pancreatic-cancer-context\" class=\"wp-block-heading\">Pancreatic Cancer Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12C Prevalence<\/strong>: Present in approximately 1\u20132% of pancreatic cancer cases<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: No approved targeted therapies specifically for KRAS G12C-mutated pancreatic cancer<\/li>\n\n\n\n<li><strong>Prognosis Challenge<\/strong>: Advanced pancreatic cancer has 5-year survival rate of &lt;3%<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: First-mover advantage in this specific molecular subset<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-kras-inhibitor-market\" class=\"wp-block-heading\">KRAS Inhibitor Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pioneering Class<\/strong>: KRAS G12C inhibitors represent breakthrough in targeting previously undruggable oncogene<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: Olomorasib&#8217;s pharmacokinetic properties may offer dosing and efficacy advantages<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Dual designation strategy demonstrates versatility across therapeutic approaches<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-eli-lilly\" class=\"wp-block-heading\">Strategic Implications for Eli Lilly<\/h2>\n\n\n\n<h3 id=\"h-oncology-portfolio-expansion\" class=\"wp-block-heading\">Oncology Portfolio Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Medicine Leadership<\/strong>: Strengthens position in biomarker-driven oncology<\/li>\n\n\n\n<li><strong>KRAS Franchise Development<\/strong>: Establishes olomorasib as cornerstone of KRAS inhibition strategy<\/li>\n\n\n\n<li><strong>Commercial Diversification<\/strong>: Addresses multiple high-value indications with single molecule<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-development-acceleration-benefits\" class=\"wp-block-heading\">Development Acceleration Benefits<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Expedited Pathway<\/strong>: Breakthrough Therapy designation enables priority review and intensive FDA guidance<\/li>\n\n\n\n<li><strong>Clinical Trial Flexibility<\/strong>: Potential for smaller, faster trials with surrogate endpoints<\/li>\n\n\n\n<li><strong>Market Access Advantage<\/strong>: Earlier approval timeline supports premium pricing and rapid adoption<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-partnership-synergy\" class=\"wp-block-heading\">Partnership Synergy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KEYTRUDA\u00ae Collaboration<\/strong>: Leverages established immunotherapy partnership with Merck<\/li>\n\n\n\n<li><strong>Biomarker Strategy<\/strong>: Aligns with industry trend toward comprehensive molecular profiling<\/li>\n\n\n\n<li><strong>Diagnostic Development<\/strong>: Drives companion diagnostic co-development opportunities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-development-strategy\" class=\"wp-block-heading\">Forward Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer Program<\/strong>: Accelerated monotherapy development pathway enabled by Breakthrough designation<\/li>\n\n\n\n<li><strong>NSCLC Combination<\/strong>: Ongoing first-line combination studies with KEYTRUDA\u00ae<\/li>\n\n\n\n<li><strong>Additional Indications<\/strong>: Potential expansion to other KRAS G12C-mutated solid tumors<\/li>\n\n\n\n<li><strong>Global Regulatory Strategy<\/strong>: U.S. Breakthrough designation may facilitate international submissions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory designations, clinical development, and commercial potential. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,199,911],"class_list":["post-71784","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71784\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71784\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:37:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:37:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer\",\"datePublished\":\"2026-08-05T16:37:34+00:00\",\"dateModified\":\"2026-08-05T16:37:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71784#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71784\",\"name\":\"Eli Lilly's KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-05T16:37:34+00:00\",\"dateModified\":\"2026-08-05T16:37:35+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71784\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71784#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71784","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer","og_description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.","og_url":"https:\/\/flcube.com\/?p=71784","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:37:34+00:00","article_modified_time":"2026-08-05T16:37:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71784#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71784"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer","datePublished":"2026-08-05T16:37:34+00:00","dateModified":"2026-08-05T16:37:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71784"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71784#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71784","url":"https:\/\/flcube.com\/?p=71784","name":"Eli Lilly's KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-05T16:37:34+00:00","dateModified":"2026-08-05T16:37:35+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and harbor a KRAS G12C mutation, as determined by an FDA-approved test.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71784#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71784"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71784#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71784"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71784\/revisions"}],"predecessor-version":[{"id":71786,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71784\/revisions\/71786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}